Eradication of MRSA biofilm-associated implant infections by low-immunogenic sustained-release lysostaphin fused to thermosensitive polypeptides
Authors present an antimicrobial characterisation of their elastin-like polypeptide-fused lysostaphin, which offers enhanced stability, low immunogenicity and sustained release via injection. It safely and completely eradicates in vivo MRSA biofilm infections, outperforming lysostaphin and vancomycin.
Authors present an antimicrobial characterisation of their elastin-like polypeptide-fused lysostaphin, which offers enhanced stability, low immunogenicity and sustained release via injection. It safely and completely eradicates in vivo MRSA biofilm infections, outperforming lysostaphin and vancomycin.